Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $100.00 price target on the stock.
Verona Pharma plc (VRNA)'s Shareholders Authorizes the $10 Billion Acquisition of Verona Pharma plc (VRNA); Nasdaq Trading to Suspend [Yahoo! Finance]
BioSpace Announces Inaugural 40 Under 40 Winners
Merck acquisition of Verona Pharma approved by court [Seeking Alpha]
Acquisition of Verona by MSD Approved by the High Court of Justice of England and Wales